KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Gains from Investment Securities (2016 - 2025)

Resmed (RMD) has disclosed Gains from Investment Securities for 15 consecutive years, with -$40.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities fell 134.43% year-over-year to -$40.8 million, compared with a TTM value of $10.7 million through Dec 2025, down 95.25%, and an annual FY2025 reading of $214.0 million, up 2343.91% over the prior year.
  • Gains from Investment Securities was -$40.8 million for Q4 2025 at Resmed, down from $61.9 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $382.7 million in Q4 2021 and bottomed at -$379.9 million in Q2 2022.
  • Average Gains from Investment Securities over 5 years is $21.3 million, with a median of $4.2 million recorded in 2023.
  • The sharpest move saw Gains from Investment Securities tumbled 140270.48% in 2022, then surged 46879.56% in 2024.
  • Year by year, Gains from Investment Securities stood at $382.7 million in 2021, then crashed by 106.2% to -$23.7 million in 2022, then soared by 132.87% to $7.8 million in 2023, then soared by 1421.7% to $118.6 million in 2024, then crashed by 134.43% to -$40.8 million in 2025.
  • Business Quant data shows Gains from Investment Securities for RMD at -$40.8 million in Q4 2025, $61.9 million in Q3 2025, and $196.5 million in Q2 2025.